SHARPE
Reported results
- GAAP net loss was $94.2 million for the third quarter of 2026, compared to $73.9 million for the third quarter of 2025.
- GAAP research and development expenses were $64.2 million for the third quarter of 2026, compared to $65.8 million for the third quarter of 2025.
- GAAP general and administrative expenses were $42.7 million for the third quarter of 2026, compared to $12.6 million for the third quarter of 2025.
- GAAP basic and diluted net loss per share attributable to common stockholders was $3.23 for the third quarter of 2026, compared to $3.36 for the third quarter of 2025.
- Cash, cash equivalents and marketable securities were approximately $1.3 billion as of September 30, 2026, compared to $926.1 million as of December 31, 2025.
Guidance
- Cash, cash equivalents and marketable securities as of September 30, 2026 are expected to fund operations into 2028.
Price and volatility reaction
The stock moved +19.9% on the print. No front-expiry chain was on file, so there is no straddle expected move.
| Measure | Value | Basis |
|---|---|---|
| Close before release | 277.62 | 2026-11-06 |
| Close after release | 332.97 | 2026-11-09 |
| Realised move | +19.9% | close to close |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-09 (8-K, Item 2.02). Read the original filing on sec.gov.